Emily Baker
Exchange PhD Student
Chimie ParisTech
PSL University
CNRS
Institute of Chemistry for Life and Health Sciences
Laboratory for Inorganic Chemical Biology
+33 1 85 78 41 53
emily.baker@chimieparistech.psl.eu
Emily was born in England, where she was raised in a small town in East Staffordshire. She completed her undergraduate (BSc) degree in Applied Biomedical Science at Aston University in 2022, where she undertook a placement year in a hospital laboratory within the Clinical Microbiology department. Here, she earned certification from the Institute of Biomedical Science to practice as a Biomedical Scientist. This is where her passion for Microbiology began.
After completing her BSc in Applied Biomedical Science, Emily began her PhD at Aston University in 2022. Her PhD is focused on the development of novel strategies for treating antibiotic resistant pathogens, including the emerging cystic fibrosis infection Mycobacterium abscessus. As part of her PhD, she is collaborating with the Gasser group to repurpose their metal-based photosensitizers as antimicrobials.
After identifying some promising hit compounds, Emily is joining the team at Chimie ParisTech for an 8 week-placement. Here, she will pursue synthesis of the most promising compounds, to enable further study of their antimicrobial applications.
Outside of the lab, Emily enjoys reading and spending quality time with her family and friends. She is excited to experience Paris, with some memorable visits from the people that mean a lot to her.
Award
2022: The Institute of Biomedical Science Certificate of Competence (Licentiate of the Institute of Biomedical Science).
Publications
[1] 2024: npj Antimicrobials & Resistance ‘Cystic fibrosis sputum media induces an overall loss of antibiotic susceptibility in Mycobacterium abscessus’. https://doi.org/10.1038/s44259-024-00054-3
[2] 2024: npj Antimicrobials & Resistance ‘Polymicrobial infection in cystic fibrosis and future perspectives for improving Mycobacterium abscessus drug discovery’. https://doi.org/10.1038/s44259-024-00060-5
[3] 2024: European Journal of Organic Chemistry ‘Aryl‐fluorocyclopropane β‐lactams with activity against Mycobacteroides abscessus and Mycobacterium bovis BCG’. https://doi.org/10.1002/ejoc.202401050
[4] 2023: Infectious Microbes & Diseases: ‘Drug Repurposing for the treatment of Mycobacterium abscessus infections’. DOI: 10.1097/IM9.0000000000000123.
[5] 2023: The Journal of Laryngology & Otology: ‘Do variations in nasal irrigation recipes and storage effect the risk of bacterial contamination?’. doi:10.1017/S0022215122002559